Jozef Michalka
Overview
Explore the profile of Jozef Michalka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
18
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kunovsky L, Eliska T, Michalka J, Trna J
United European Gastroenterol J
. 2025 Jan;
PMID: 39801245
No abstract available.
2.
Desai S, Spinner M, Evens A, Sykorova A, Bachanova V, Goyal G, et al.
Blood Adv
. 2023 Sep;
7(23):7295-7303.
PMID: 37729621
In the pre-novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3...
3.
Kubes V, Kren L, Sokol F, Michalka J, Muzik J, Arpas T, et al.
In Vivo
. 2023 Jun;
37(4):1735-1742.
PMID: 37369476
Background/aim: Classic Hodgkin lymphoma (cHL) is a common B-cell malignancy. Despite the good prognosis, in some patients the standard chemotherapy and radiotherapy-based approach does not lead to long-term remission, and...
4.
Prochazka V, Belada D, Janikova A, Benesova K, Mocikova H, Duras J, et al.
EJHaem
. 2022 Jul;
1(1):170-180.
PMID: 35847728
Twenty percent of patients with high-tumor-burden (HTB) follicular lymphoma (FL) develop progression/relapse of disease (POD) within 24 months of frontline immunochemotherapy. Unfortunately, about 50% of these patients die within 5...
5.
Trizuljak J, Petruchova T, Blahakova I, Vrzalova Z, Horinova V, Doubkova M, et al.
Mol Syndromol
. 2020 Jul;
11(2):73-82.
PMID: 32655338
Bloom syndrome is an autosomal recessive disorder characterized by prenatal and postnatal growth deficiency, photosensitive skin changes, immune deficiency, insulin resistance, and a greatly increased risk of early-onset cancer and...
6.
Janikova A, Michalka J, Bortlicek Z, Chloupkova R, Campr V, Kopalova N, et al.
Ann Hematol
. 2020 Jun;
99(7):1583-1594.
PMID: 32506244
Relapsing diffuse large B cell lymphomas (rDLBCL) represent a heterogeneous disease. This heterogeneity should be recognized and reflected, because it can deform the interpretation of clinical trial results. DLBCL patients...
7.
Kral Z, Michalka J, Mocikova H, Markova J, Sykorova A, Belada D, et al.
J Cancer
. 2019 Oct;
10(21):5041-5048.
PMID: 31602255
: Clinical trials have demonstrated the effectiveness of the CD30-targeted antibody-drug conjugate brentuximab vedotin (BV) for the treatment of relapsed/refractory Hodgkin lymphoma (R/R HL). In this study, we report on...
8.
Mocikova H, Pytlik R, Stepankova P, Michalka J, Markova J, Koren J, et al.
Acta Haematol
. 2015 May;
134(3):187-92.
PMID: 26021284
Background: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma showing strong CD20 expression. The role of rituximab in treating NLPHL still needs clarification. Methods: We retrospectively...